NCT03036930 2026-03-11
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
61 trialsNCT07209189 2026-03-09
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07418034 2026-02-18
SAVED
University of Maryland, Baltimore
Phase 2 Not yet recruiting
NCT01932697 2026-02-10
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Mayo Clinic
Phase 2 Completed
NCT05797246 2026-01-26
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06756269 2025-12-17
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 2 Recruiting
NCT06210854 2025-10-23
Assessing Jet Administration of pBI-11 for the Treatment of Patients With HPV16/18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Not yet recruiting
NCT04098744 2025-10-02
ART-CIN_IIB
Frantz Viral Therapeutics, LLC
Phase 2 Recruiting
NCT06075264 2025-08-14
ART-VIN IIB
Frantz Viral Therapeutics, LLC
Phase 2 Recruiting
NCT05388773 2025-06-19
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT06793410 2025-06-05
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Vastra Gotaland Region
Phase 2 Recruiting
NCT05555862 2025-05-18
anal HSIL HIV-
Frantz Viral Therapeutics, LLC
Phase 2 Active not recruiting
NCT01898494 2025-02-28
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03487549 2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT06705322 2024-11-26
Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix.
Fudan University
Phase 2 Not yet recruiting
NCT06686043 2024-11-13
HPV-VIM
Baylor College of Medicine
Phase 2 Recruiting
NCT06681636 2024-11-08
HPV9vxFSW
National Institute of Hygiene and Epidemiology, Vietnam
Phase 2 Not yet recruiting
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT06439433 2024-06-03
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT03258008 2022-12-16
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01693783 2022-11-08
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04436133 2022-05-06
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
National Vaccine and Serum Institute, China
Phase 2 Completed
NCT03937791 2021-04-13
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT04044950 2020-09-22
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01209325 2020-08-11
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
AIDS Malignancy Consortium
Phase 2 Completed
NCT00586339 2020-01-03
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
GlaxoSmithKline
Phase 2 Completed
NCT00359619 2020-01-02
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
GlaxoSmithKline
Phase 2 Completed
NCT00231413 2019-12-12
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
GlaxoSmithKline
Phase 2 Completed
NCT02631863 2019-07-08
Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT03584308 2019-05-22
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
Catalysis SL
Phase 2 Completed
NCT02706691 2019-04-16
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
University of Chicago
Phase 2 Terminated
NCT00309166 2018-09-17
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.
GlaxoSmithKline
Phase 2 Completed
NCT02048020 2018-08-14
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02724254 2018-07-20
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Vaxart
Phase 2 Completed
NCT00546078 2018-06-26
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
GlaxoSmithKline
Phase 2 Completed
NCT01585428 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02640820 2018-02-23
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyproneâ„¢) on the Clearance of Verruca Vulgaris (Common Warts)
RXi Pharmaceuticals, Corp.
Phase 2 Unknown
NCT03372395 2017-12-13
Probiotic Implementation as Help in Solving Vaginal Infections
University of Roma La Sapienza
Phase 2 Completed
NCT03302858 2017-10-05
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand
Laser Surgery Care
Phase 2 Unknown
NCT02139267 2017-07-12
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
Genexine, Inc.
Phase 2 Completed
NCT02596243 2017-07-12
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
Genexine, Inc.
Phase 2 Unknown
NCT02015260 2017-05-03
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
University of Aberdeen
Phase 2 Completed
NCT00411749 2017-04-21
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00378560 2017-04-17
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00518336 2016-12-09
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
GlaxoSmithKline
Phase 2 Completed
NCT00120848 2016-11-04
Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults
GlaxoSmithKline
Phase 2 Completed
NCT00312286 2016-09-23
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
Takeda
Phase 2 Terminated